Septerna

SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

HSDT

HUBC

LSTA

NEHC

NFLX

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

Septerna Inc

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Earnings

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Septerna to Present at Jefferies Global Healthcare Conference

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Health Care

Septerna to Participate in Upcoming Investor Conferences

Small Cap

Management

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

ATAI Life Sciences

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Innoviva

Maze Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nektar Therapeutics

Oculis Holding

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Trevi Therapeutics

Zevra Therapeutics

Cantor Fitzgerald

HC Wainwright & Co.

Wells Fargo

JP Morgan

Comments

Septerna

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL